Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

AstraZeneca Settles Ultomiris-Related Patent Litigation With Chugai

  • Alexion Pharmaceuticals, a unit of AstraZeneca plc (NASDAQ:AZN), has entered into a settlement agreement with Chugai Pharmaceutical Co Ltd, resolving all patent disputes related to Ultomiris (ravulizumab).
  • Under the settlement agreement, Alexion and Chugai will withdraw patent infringement proceedings filed with the U.S. District Court for the District of Delaware and Tokyo District Court. 
  • Alexion will make a single payment of $775 million in Q2 of 2022, for which a charge will be recognized through the non-core P&L in Q1 of 2022. 
  • No additional amounts are payable by either party. The settlement does not impact AstraZeneca’s financial guidance for 2022.
  • In November 2018, Chugai filed a lawsuit against Alexion alleging that Ultomiris infringes US patent No. 9,890,377 held by Chugai. Upon issuing US patent No. 10,472,623 in November 2019, Chugai filed a second lawsuit in the same court alleging that Ultomiris also infringes that patent. 
  • The two lawsuits were consolidated in December 2019.
  • Marc Dunoyer, Chief Executive Officer, Alexion, said: “With this settlement, we will continue to advance our Ultomiris development programs in new indications and focus on our mission to transform the lives of people affected by rare diseases.”
  • Price Action: AZN shares are down 0.05% at $61.93 during the premarket session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.